Innovent Biologics Inc (6IB) - Total Liabilities

Latest as of December 2025: €17.99 Billion EUR ≈ $21.03 Billion USD

Based on the latest financial reports, Innovent Biologics Inc (6IB) has total liabilities worth €17.99 Billion EUR (≈ $21.03 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Innovent Biologics Inc - Total Liabilities Trend (2016–2025)

This chart illustrates how Innovent Biologics Inc's total liabilities have evolved over time, based on quarterly financial data. See Innovent Biologics Inc current assets vs equity to evaluate short-term liquidity relative to the company's equity base.

Innovent Biologics Inc Competitors by Total Liabilities

The table below lists competitors of Innovent Biologics Inc ranked by their total liabilities.

Company	Country	Total Liabilities
Capgemini SE PA:CAP	France	€17.39 Billion
Lingyi iTech Guangdong Co SHE:002600	China	CN¥31.34 Billion
Wipro Limited F:WIOA	Germany	€512.90 Billion
PTT Exploration and Production Public Company Limited BK:PTTEP	Thailand	฿455.09 Billion
Hyundai Rotem Co KO:064350	Korea	₩3.64 Trillion
Hitachi Energy India Limited NSE:POWERINDIA	India	Rs51.79 Billion
Trent Limited NSE:TRENT	India	Rs46.21 Billion
FIBRA Prologis MX:FIBRAPL14	Mexico	MX$42.31 Billion

Liability Composition Analysis (2016–2025)

This chart breaks down Innovent Biologics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Innovent Biologics Inc (6IB) total market value.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	2.62	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.93	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.48	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Innovent Biologics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Innovent Biologics Inc (2016–2025)

The table below shows the annual total liabilities of Innovent Biologics Inc from 2016 to 2025.

Year	Total Liabilities	Change
2025-12-31	€17.99 Billion ≈ $21.03 Billion	+112.04%
2024-12-31	€8.48 Billion ≈ $9.92 Billion	+4.75%
2023-12-31	€8.10 Billion ≈ $9.47 Billion	+18.09%
2022-12-31	€6.86 Billion ≈ $8.02 Billion	+15.99%
2021-12-31	€5.91 Billion ≈ $6.91 Billion	+93.55%
2020-12-31	€3.06 Billion ≈ $3.57 Billion	+23.47%
2019-12-31	€2.47 Billion ≈ $2.89 Billion	+29.00%
2018-12-31	€1.92 Billion ≈ $2.24 Billion	-52.98%
2017-12-31	€4.08 Billion ≈ $4.77 Billion	+8.09%
2016-12-31	€3.77 Billion ≈ $4.41 Billion	--

About Innovent Biologics Inc

F:6IB Germany Biotechnology

Market Cap

$16.83 Billion

€14.39 Billion EUR

Market Cap Rank

#1515 Global

#333 in Germany

Share Price

€8.30

Change (1 day)

+2.28%

52-Week Range

€7.96 - €11.60

All Time High

€11.80